The Pharmacy Times® COVID-19 Resource Center is a comprehensive resource for clinical news and expert insights on COVID-19, an infectious disease caused by the SARS-CoV-2 virus, including vaccine information and treatments for the disease.
September 4th 2025
Azelastine, commonly used in nasal sprays to combat allergies, was found to reduce the incidence of SARS-CoV-2 among healthy controls in a phase 2 trial.
August 28th 2025
COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.
August 27th 2025
The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.
August 26th 2025
Rhinovirus infection, which causes the common cold, could offer infected children more respiratory pathway protection from SARS-CoV-2 infection.
August 20th 2025
The development of multisystem inflammatory syndrome in children infected with SARS-CoV-2 was associated with more marked shifts in metabolic parameters, leading to increased cardiovascular disease risk.
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children at Increased Risk
Published: July 10th 2025 | Updated: July 10th 2025mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk features for severe COVID-19.
Read More
FDA Recommends 2025-2026 COVID-19 Vaccines Be Monovalent, Target LP.8.1 Strain
May 27th 2025Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced its recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.
Read More
FDA to Restrict Future COVID-19 Vaccine Recommendations to Older Adults, High-Risk Groups
May 21st 2025In a major policy shift, officials from the FDA announced a new regulatory framework for COVID-19 vaccinations, prioritizing adults 65 years and older and individuals with serious comorbidities putting them at high risk for severe COVID-19.
Read More
The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.
Read More
Inhaled siRNA-Based MIR 19 Reduces Progression to Severe Disease in Outpatients With Mild COVID-19
April 16th 2025With a more direct mechanism of action against viral replication compared with standard treatments, the small interfering RNA (siRNA)-based MIR 19 treatment could revolutionize outpatient COVID-19 treatment.
Read More
Financial Incentives for COVID-19 Vaccination May Have Adverse Spillover Effects on Booster Uptake
April 9th 2025Monetary incentives to receive a COVID-19 vaccine at a public vaccination event may have inadvertently turned away others from receiving a booster, emphasizing the importance of recognizing spillover in trials addressing vaccine hesitancy.
Read More
Marcella Kinaya, PharmD, on Flu Season: ‘We’re Here to Protect People and Make Sure They’re Healthy’
March 25th 2025A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.
Read More
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831